Other UPR-targeted pharmacological agents that synergize with anticancer drugs to amplify their effects include integrated stress response inhibitor B (ISRIB) [189], which reverses eIF2α phosphorylation and enhances gemcitabine-induced pancreatic cancer cell death, MKC-3946 [190], which enhances bortezomib or arsenic trioxide tumor-killing effects in acute myeloid leukemia cells by inhibiting IRE1α ribonuclease (RNase), and epigallocatechin gallate (EGCG), which directly targets HSPA5 to resensitize glioma cells to temozolomide chronotherapy [191]. Here, EIF2A is linked to pancreatic neoplasm.